RegulationBreakthrough Therapy (United States), Fast Track (United States), Emergency Use Authorization (United States), Orphan Drug (United States), Orphan Drug (Japan), Priority Review (United States), Special Review Project (China)

Structure/Sequence

Molecular FormulaC16H17N7O2S

InChIKeyXUZMWHLSFXCVMG-UHFFFAOYSA-N

CAS Registry1187594-09-7

238

Clinical Trials associated with Baricitinib

NCT07081763

/ Not yet recruitingPhase 2IIT

Immunotherapy With a JAK1/JAK2 Inhibitor (Baricitinib) and an mTORC1 Inhibitor (Sirolimus), Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption: a Phase II Multicenter, Multi-arm, Multi-stage, Randomized, Double-blind, Placebo-controlled, Adaptative Trial

Natural HIV controllers (HICs) and post-treatment controllers (PTCs) are rare examples of people living with HIV (PLWH) who achieve control of HIV replication without the need for antiretroviral therapy (ART). Therapeutic strategies that can induce such a phenotype are therefore a key goal in the quest for a remission of HIV infection.
JAK1/JAK2 and mTORC1 are key biological pathways involved in the regulation of HIV-1 transcription and replication, as well as the functional capacities of immune effectors, primarily CD8 T cells (exhaustion status and immunometabolic properties), but also NK cells. Immunotherapeutic interventions using a JAK1/JAK2 inhibitor and an mTORC1 inhibitor, alone or in combination to achieve an additive or synergistic effect, are therefore promising candidates to induce a PTC-like phenotype. The use of combined approaches of immunotherapies with different and potentially complementary effects may increase the likelihood of achieving viral control.
This study aims at evaluating the efficacy and safety of three experimental immunotherapeutic interventions (i.e., baricitinib, a JAK1/JAK2 inhibitor, alone; sirolimus, an mTORC1 inhibitor, alone; or their combination) on viral control following an analytic treatment interruption (ATI) of antiretroviral drugs in PLWH who had initiated ART during primary HIV-1 infection. This randomized clinical trial will use an innovative multi-arm multi-stage adaptive design.

Start Date01 May 2026

Sponsor / Collaborator-

NCT06381661

/ Not yet recruitingPhase 3IIT

PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

Start Date01 Apr 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT06923072

/ RecruitingPhase 2IIT

A Phase IIa Trial of Baricitinib in the Treatment of Kohlmeier-Degos Disease Patients With Neurological Involvement

Background:
Kohlmeier-Degos (KD) is a rare disease that causes inflammation and blood clots, leading to blockages in small blood vessels. These blockages can result in K-D lesions throughout the body, affecting the skin, lungs, heart, spinal cord, and brain. KD can be fatal. No treatment exists for this disease.
Objective:
To test a study drug (baricitinib) in people with brain and spine lesions caused by KD disease. Baricitinib is FDA approved to treat other disorders but has not yet been tried in people with KD.
Eligibility:
People aged 18 years or older with KD-related lesions in the brain and spine.
Design:
Participants will be screened; they will have a physical exam with blood tests. They will also have a baseline visit that may include multiple tests, such as imaging scans of the brain and spine; a lumbar puncture to collect fluid from the spinal canal; and a meeting with a neurologist. They will fill out a questionnaire about their health. They will continue to take their normal medications throughout the study.
Baricitinib is a tablet taken by mouth. Participants will remain on their normal medications for 12 weeks after their baseline visit. Then they will also take the study drug once a day at home for 24 weeks.
Participants will have clinic visits every few weeks for up to 40 weeks. Some visits may take 1 to 4 days. Baseline tests will be repeated 3 more times during study visits. Other visits will require only blood tests; these may be done by local labs that will send the samples to NIH; 2 visits may be done via telehealth....

Start Date02 Sep 2025

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with Baricitinib

100 Translational Medicine associated with Baricitinib

100 Patents (Medical) associated with Baricitinib

3,478

Literatures (Medical) associated with Baricitinib

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials

Review

Author: Ji, Chao ; Lv, Xiaoqing ; Qin, Kun ; Mao, Jing ; Ou, Yushan ; Ruan, Shifan ; Su, Xinhong

BACKGROUND:

Emerging research suggests that Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors may be associated with a higher risk of serious infection for patients with rheumatoid arthritis. However, there is no consensus on whether JAK inhibitors increase the risk of serious infection in patients with Immune-mediated inflammatory skin diseases (IMISDs).

OBJECTIVES:

To ascertain the correlation between JAK inhibitor use and the risk of serious infection in patients with IMISDs.

METHODS:

PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and registered Clinical Trials were searched up to June 1, 2024, using specific search terms related to JAK inhibitors and IMISDs. Randomized clinical trials (RCTs) comparing JAK inhibitors with a control group in patients with IMISDs were included. Studies focusing on cohort studies, case reports, case series, review articles, pooled analysis studies, post hoc analyses and topical JAK inhibitors were excluded. Data were extracted independently by two authors, focusing on serious infections defined according to each study's criteria. Crude numbers for serious infections were pooled and underwent meta-analysis. We assessed the primary outcome regarding the occurrence of severe infections for each study.

RESULTS:

Thirty-two randomized clinical trials involving 11,917 patients were included. Serious infections were reported in 0.62% of patients receiving JAK inhibitors and 0.51% of controls. Meta-analysis found no significant increase in risk of serious infection (I²=0.00%, RR, 0.68; 95% CI, 0.43-1.07). Subgroup analyses revealed no significant heterogeneity based on condition (p = .56) or medication (p = .69).

CONCLUSIONS:

This meta-analysis demonstrates that JAK inhibitors do not significantly increase the risk of serious infections in IMISD patients compared to control treatments. These findings support the safety of JAK inhibitors in this population. Future research should focus on real-world evidence to further assess their risk-benefit profile in dermatological practice.

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation

Letter

Author: Flinn, A M ; Browne, F ; Blokhuis, C ; Irvine, A D ; Leahy, T R

01 Dec 2025·Current Hematologic Malignancy Reports

Emerging Therapeutic Approaches for Anemia in Myelofibrosis

Review

Author: Harrington, Patrick ; Palumbo, Giuseppe A ; Chifotides, Helen T ; Duminuco, Andrea ; Bose, Prithviraj ; Torre, Elena ; Vetro, Calogero

PURPOSE OF REVIEW:

In this review, we highlight conventional agents and novel emerging therapeutic strategies to treat anemia in MF.

RECENT FINDINGS:

Anemia is a common and challenging feature of myelofibrosis (MF). The pathobiology of anemia is multifactorial, including progressive bone marrow fibrosis, decreased erythropoiesis due to high hepcidin levels leading to iron sequestration in the reticuloendothelial system, hypersplenism, erythropoiesis inhibition by myelosuppressive JAK inhibitors (ruxolitinib, fedratinib), and others. MF-associated anemia has a negative impact on survival. Conventional agents to manage anemia include erythropoiesis-stimulating agents, danazol, corticosteroids, and immunomodulatory agents, but responses are infrequent and lack durability. Notable advancements have emerged in developing novel treatments for anemia in MF, including the regulatory approval of momelotinib (ACVR1/JAK1/2 inhibitor) in 2023 and development of novel promising agents targeting hemojuvelin and activins. Momelotinib and pacritinib (ACVR1/JAK2 inhibitor) are the preferred JAK inhibitors for patients with cytopenias (anemia, thrombocytopenia). Luspatercept and elritercept are activin receptor ligand traps, promoting erythroid maturation and late-stage erythropoiesis. Currently, luspatercept is being evaluated in a phase 3 trial (INDEPENDENCE™) for anemia in MF patients who are on a JAK2 inhibitor and require transfusions, and in a phase 2 trial (ODYSSEY) in combination with momelotinib in MF patients who are transfusion dependent, whether or not on a JAK inhibitor. Interim results of the RESTORE trial demonstrated that elritercept significantly decreased transfusions in MF patients. DISC-0974 is a first-in-class anti-hemojuvelin (positive hepcidin regulator) monoclonal antibody that decreased hepcidin expression, increased serum iron, and enhanced erythropoiesis in anemic patients with MF in a phase 1b/2 study. Burgeoning studies of novel anemia-targeted agents and combinations are significantly improving the quality of life and outcomes of patients with MF. The recent approval of momelotinib to treat MF with anemia and the emerging novel anemia-directed strategies in early and advanced clinical development have ushered in a new era in the treatment of MF-related anemia.

729

News (Medical) associated with Baricitinib

22 Aug 2025

·pipelinereview.com

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV ) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ ® ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage). 1 In Study 1, both doses of upadacitinib achieved the primary endpoint, with 45.2% and 55.0% of patients treated with upadacitinib 15 mg and 30 mg, respectively, reaching 80% or more scalp hair coverage (SALT score ≤ 20) at week 24, compared to 1.5% of patients receiving placebo (p<0.001). 1 These results are consistent with the topline results previously announced from the first parallel replicate study (Study 2) of the Phase 3 UP-AA clinical program. “These positive results strengthen the growing body of evidence supporting the potential of upadacitinib to improve the lives of people with AA,” said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. “We are very encouraged by the improvements in both scalp and non-scalp hair regrowth observed with both doses of upadacitinib and look forward to submitting these data to regulatory bodies, bringing us one step closer to delivering upadacitinib to those living with this complex immune-mediated disease.” 35.2% and 45.8% of patients treated with upadacitinib 15 mg and 30 mg, respectively, reached 90% or more scalp hair coverage (SALT ≤ 10), compared to 0.7% of patients receiving placebo at week 24 (p<0.001). 1 Additional key secondary endpoints that were met included percentage of subjects with improvements in eyebrows and eyelashes, as well as the percentage of subjects with complete scalp hair coverage (SALT=0) with both doses of upadacitinib at week 24. 1 “People living with AA often face considerable uncertainty related to both the severity and duration of hair loss, despite current treatment options,” said Arash Mostaghimi, M.D., M.P.A., M.P.H., associate professor of dermatology and vice chair of clinical trials and innovation, Brigham & Women’s Hospital, Harvard Medical School. “These encouraging results are consistent with and reinforce the outcomes observed in the first pivotal trial. Together, these findings underscore the potential of upadacitinib to provide meaningful hair regrowth, offering hope for those enduring the psychosocial burden associated with this disease.” The safety profile of both doses of upadacitinib in the 24-week, placebo-controlled period (Period A) was generally consistent with that observed in approved indications. 1 Treatment-emergent serious adverse events occurred in 1.9% and 1.8% of patients in the upadacitinib 15 mg and 30 mg groups, respectively, and 0.7% in the placebo group. 1 Discontinuations due to treatment-emergent adverse events (TEAEs) occurred in 1.1% and 1.5% of patients in the upadacitinib 15 mg and 30 mg groups, respectively, and none in the placebo group. 1 The most common TEAEs observed were upper respiratory tract infection, acne, blood creatine phosphokinase increased and nasopharyngitis. 1 Serious infections were reported infrequently with one in the placebo group and one in the upadacitinib 30 mg group, and none in the upadacitinib 15 mg group group. 1 There were no adjudicated MACE, adjudicated venous thromboembolic events or deaths reported. 1 One malignancy (breast cancer) was reported in the upadacitinib 15 mg group. 1 Use of upadacitinib in AA is not approved and its safety and efficacy have not been evaluated by regulatory authorities. About UP-AA Clinical Trial UP-AA M23-716 was conducted as a single protocol that includes two replicate pivotal studies (Study 1 and Study 2) with randomization, investigative sites, data collection, analysis and reporting independent for each study. The Phase 3 randomized, placebo-controlled, double-blind studies evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata. In Study 1 and Study 2 Period A, participants are randomized to one of three groups to receive upadacitinib 15 mg, upadacitinib 30 mg or placebo for 24 weeks. In Study 1 and Study 2 Period B, participants originally randomized to upadacitinib dose groups in Period A will continue their same treatment in Period B for 28 weeks. Participants originally randomized to placebo in Period A will either remain on placebo in Period B, or be randomized in one of two groups, based off of their SALT score at week 24. In total, Study 1 and Study 2 Periods A and B span 52 weeks. Participants who complete Study 1 or Study 2, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. The two trials randomized 1,399 participants with severe AA ages 12 to 64 across 248 sites worldwide. More information on this trial can be found at www.clinicaltrials.gov ( NCT06012240 ). About RINVOQ Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. In human leukocyte cellular assays, RINVOQ inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. 2 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known. Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus and vitiligo. 3,4,5,6,7 RINVOQ (upadacitinib) U.S. Uses and Important Safety Information 1 RINVOQ is a prescription medicine used to treat: Please click here for the Full Prescribing Information and Medication Guide . Globally, prescribing information varies; refer to the individual country product label for complete information. About AbbVie AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn, Facebook , Instagram , X (formerly Twitter) and YouTube. 1 AbbVie. Data on file ABVRRTI81580. 2 RINVOQ [Package Insert]. North Chicago, IL: AbbVie Inc.; 2025. 3 A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants with Takaysu Arteritis (TAK) (SELECT-TAK). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT04161898 . Accessed January 15, 2025. 4 Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT05843643 . Accessed January 15, 2025. 5 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT05889182 . Accessed January 15, 2025. 6 A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT06118411 . Accessed January 15, 2025. 7 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT06012240 . Accessed January 15, 2025. SOURCE: AbbVie

Clinical ResultPhase 3Phase 2

22 Aug 2025

·firstwordpharma.com

AbbVie's Rinvoq scores second late-stage win in alopecia

AbbVie is planning regulatory submissions for Rinvoq (upadacitinib) to treat hair loss after it shared that the JAK inhibitor has now succeeded in both Phase III trials comprising the UP-AA clinical programme.The results of Study 1 were reported Thursday, less than a month after AbbVie announced that the programme's Study 2 met its clinical endpoint. The two replicate pivotal studies enrolled 1,399 patients between the ages of 12 and 64 with severe alopecia areata (AA) and a mean baseline scalp hair coverage of about 16%. Participants were randomised to take either a 15-mg or 30-mg oral, once-daily dose of Rinvoq, or placebo.In Study 1, 55% of patients who received the high dose of Rinvoq, and 45.2% of those on the low dose, experienced 80% or more scalp hair coverage at week 24, equating to a severity of alopecia tool (SALT) score of ≤ 20. The results for both doses were statistically significant compared with the placebo group, of which only 1.5% of patients achieved a SALT score of ≤ 20, meeting the primary endpoint. The findings align with Study 2, in which 54.3% and 44.6% of patients taking 30-mg and 15-mg doses of Rinvoq, respectively, reached 80% or more scalp hair coverage at week 24.AbbVie also reported that several key secondary endpoints in Study 1 were met, including improvements in eyebrows and eyelashes, as well as the percentage of patients who had complete scalp hair coverage, though the pharma didn't disclose specific figures for either measure. The JAK inhibitor's safety profile was consistent with its approved label, AbbVie said. Serious treatment-emergent adverse events (TEAEs) occurred in 1.9% and 1.8% of patients who received 15 mg and 30 mg Rinvoq, respectively, versus 0.7% for placebo. Additionally, 1.1% of patients in the low-dose cohort, and 1.5% in the high-dose group, discontinued treatment due to TEAEs, while none in the placebo arm did. The most common TEAEs were upper respiratory tract infection, acne, blood creatine phosphokinase increases and nasopharyngitis."We are very encouraged by the improvements in both scalp and non-scalp hair regrowth observed with both doses of upadacitinib and look forward to submitting these data to regulatory bodies," commented Kori Wallace, global head of immunology clinical development at AbbVie.An alopecia approval could help boost Rinvoq's revenues to new heights. The JAK inhibitor brought in global sales of $2.03 billion in the second quarter, up 41.8% year-over-year (see – Spotlight On: What AbbVie said on its Q2 earnings call…).

Clinical ResultPhase 3Phase 2

21 Aug 2025

·www.fiercepharma.com

AbbVie strengthens Rinvoq's case to treat alopecia, will send data to regulators

AbbVie's Rinvoq has posted phase 3 results that suggest it can be a highly effective treatment for alopecia areata. The company said it will submit results to regulatory authorities. For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA).The second replicate study in the AbbVie trial program achieved its primary endpoint, as 45.2% and 55% of patients who received respective 15 mg and 30 mg daily doses of Rinvoq reached 80% or more of scalp coverage after 24 weeks. The results were similar to those from a parallel study—with the same parameters—in which 44.6% and 54.3% of patients achieved the scalp coverage standard.Nearly 1,400 patients enrolled in the studies at a baseline mean of roughly 16% scalp hair coverage, as determined by the severity of alopecia tool (SALT), AbbVie said. In the newly reported study, 1.5% patients who received placebo reached the 80% coverage standard, while in the parallel study, 3.4% of patients on placebo hit that mark.“We are very encouraged by the improvements in both scalp and non-scalp hair regrowth observed with both doses of upadacitinib and look forward to submitting these data to regulatory bodies,” Kori Wallace, M.D., Ph.D., AbbVie’s global head of immunology clinical development, said in a statement.Additionally, in the recent study, 35% and 46% of patients treated with 15 mg and 30 mg daily doses of Rinvoq, respectively, reached 90% or more of scalp coverage at week 24. This result compared with 0.7% for those on placebo.As for secondary endpoints, both studies achieved their objectives in eyebrow and eyelash improvements. Another secondary objective that was achieved in both studies was the number of patients in each dosage group who gained complete scalp coverage at week 24.The safety profile of both doses of Rinvoq was consistent with that observed in approved indications, AbbVie said. While cross-trial comparisons are often problematic, Rinvoq appears to provide better results than three other JAK inhibitors currently on the market in the indication.The most recently approved treatment for alopecia, Sun Pharma’s Leqselvi, was tested in 1,220 patients in two trials who had a mean baseline scalp coverage of 13%. At the 24-week mark, more than 30% of patients saw their scalp coverage increase to at least 80%.Eli Lilly’s Olumiant was approved in 2022 for alopecia based on trials that showed between 17% and 22% of patients taking a 2 mg daily dose achieved 80% scalp coverage after 36 weeks, while 32% to 35% of patients taking a 4 mg daily dose reached the same standard. Pfizer’s Litfulo was approved in 2023 after a study showed 23% of patients reached 80% or more of scalp coverage after six months of treatment. Last month, AbbVie reported Rinvoq’s second-quarter sales at $2.03 billion, a 42% year-over-year increase. The product generated $5.97 billion in revenue last year.The treatment hit the market in 2019 to treat patients with rheumatoid arthritis. Since then, it has been cleared in several other indications, including psoriatic arthritis, atopic dermatitis, Crohn’s disease and ulcerative colitis.

Clinical ResultPhase 3Drug Approval

100 Deals associated with Baricitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D10308	Baricitinib	L04AA37	DB11817

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Enthesitis-Related Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Enthesitis-Related Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Enthesitis-Related Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Enthesitis-Related Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
COVID-19	Switzerland	Eli Lilly & Co.	19 Jun 2017
Alopecia Areata	European Union	Eli Lilly Nederland BV	13 Feb 2017
Alopecia Areata	Iceland	Eli Lilly Nederland BV	13 Feb 2017
Alopecia Areata	Liechtenstein	Eli Lilly Nederland BV	13 Feb 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aicardi-Goutieres Syndrome	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Melorheostosis	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Nakajo Syndrome	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
STING-associated Vasculopathy With Onset in Infancy	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Systemic onset juvenile chronic arthritis	Phase 3	Japan	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Argentina	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Belgium	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Brazil	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Czechia	Eli Lilly & Co.	12 Feb 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06662721 (Pubmed \| Rheumatology (Oxford))	Phase 2	Takayasu Arteritis TNF-α inhibitors	10	Baricitinib 4 mg daily	atcoxqdmly(fqvdamhpdq) = obvozfsbmt gzhawnkosn (xzkgzrsjyz ) View more	Positive	24 May 2025
SLE-BRAVE-I and SLE-BRAVE-II (Pubmed \| PLoS One)	Phase 3	Systemic Lupus Erythematosus	1,535	Baricitinib 4 mg	immcuperqd(avgnwefhmv) = kpjjhzrhta euxrzvrunl (cofopcfecp )	Negative	30 Apr 2025
				Baricitinib 2 mg	immcuperqd(avgnwefhmv) = szzzrydfsx euxrzvrunl (cofopcfecp )
BRAVE-AA1 and BRAVE-AA2 (Pubmed \| Am J Clin Dermatol)	Phase 3	Alopecia Areata	1,303	Baricitinib 2 mg	voqntfozsf(vxipyjoxzq) = ntedaodliy rugrmfzrxv (ldsepzncfl ) View more	Positive	11 Apr 2025
				Baricitinib 4 mg	voqntfozsf(vxipyjoxzq) = auafcvhggn rugrmfzrxv (ldsepzncfl ) View more
BRAVE-AA1; BRAVE-AA2 (Pubmed \| Br J Dermatol)	Not Applicable	Alopecia Areata	-	Baricitinib 2 mg	pydmuvlzfr(fwuyixpzzx) = vxhnxudvju wkibdwbujo (etpbnahdhh )	Positive	03 Apr 2025
				Baricitinib 4 mg	pydmuvlzfr(fwuyixpzzx) = tqqpxwrylz wkibdwbujo (etpbnahdhh )
NCT05723198 (BRAVE-AA-PEDS, Company_Website) Manual	Phase 3	Alopecia Areata	257	Baricitinib 4 mg	uemsnxfmyj(gvbeglpxul) = vvfmfmrpxi vpqhojgeza (sykbduacwv ) View more	Positive	08 Mar 2025
				BaricitinibBaricitinib 2 mg	uemsnxfmyj(gvbeglpxul) = bbvdwrmnwt vpqhojgeza (sykbduacwv ) View more
NCT03952559 (BREEZE-AD-PEDS, Pubmed \| J Dermatolog Treat)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	467	Baricitinib 4-mg equivalent	aleadoeffq(ytqwbjakcw) = oldoxnhmjp szurrteeyo (kfhdsfubqi )	Positive	31 Dec 2024
NCT01885078 (RA-BEYOND, Pubmed \| Rheumatology (Oxford)) Manual	Phase 3	Rheumatoid Arthritis	-	Baricitinib 4 mg	dbjeehruwt(fempvhufys) = xkobeiekpk alubqyigkb (edmslstfnq ) View more	Positive	01 Oct 2024
				Baricitinib 2 mg	dbjeehruwt(fempvhufys) = ztxddidbbn alubqyigkb (edmslstfnq ) View more
NCT04088409 (CTgov)	Phase 3	Uveitis, Anterior \| Uveitis \| Juvenile Idiopathic Arthritis	30	Baricitinib (Baricitinib)	vxccfltkkk = lwixgnttmq rvmdwhsztp (ygkscoacbs, jnlyzgmdgf - bbuzepgpyl) View more	-	13 Aug 2024
				Adalimumab (Adalimumab)	dmxwoxbhix(lluhzowccu) = wnbuapnjmn splxmwtkna (ugfonlaoju, rgoiifovfp - ykzddffkvk) View more
NCT03570749 \| NCT03899259 (BRAVE-AA1; BRAVE-AA2, Pubmed)	Phase 3	Alopecia Areata	131	Baricitinib 4 mg	qyjslvewyd(qybmaqkksc) = progressive improvements ndmqwirika (utflgtiuas ) View more	Positive	21 Jun 2024
				Baricitinib 2 mg
EULAR2024 Manual	Not Applicable	Lung Diseases, Interstitial	60	Baricitinib	tfxlrtetju(hbzggtrcwb) = vspyudlhzb dwjhkqotrg (gvdsrkdyin ) View more	Positive	05 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Baricitinib

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation